Someone sent me this morning a refreshing editorial on the QALY/Threshold discussion. Its funny, well written and to the point. Definitely worth a read!
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEif0j4YJ1tz7VgLZgHp_fbPYwh9SDkWOjZ8GfUamLnPf08H0t2i4kd-kqR8T0ZgrtKjP5OH1rsxqHVjiwfG4yQJ1BCbK_cE4t8LxfUMUdXIhU9MNZmKRaVtDZKyNcfqFgUyqkSh7Jff7b8/s400/dollar+sign.jpg)
Pharmacoeconomics 2008; 26 (1): 1-4
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEif0j4YJ1tz7VgLZgHp_fbPYwh9SDkWOjZ8GfUamLnPf08H0t2i4kd-kqR8T0ZgrtKjP5OH1rsxqHVjiwfG4yQJ1BCbK_cE4t8LxfUMUdXIhU9MNZmKRaVtDZKyNcfqFgUyqkSh7Jff7b8/s400/dollar+sign.jpg)
Pharmacoeconomics 2008; 26 (1): 1-4
Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf
No comments:
Post a Comment